Table 3.
Investigator-assessed antitumor activity of mobocertinib in NSCLC patients with EGFRex20ins
| 5–40 mg daily (n=12) | 80 mg total daily dosea (n=9) | 120 mg daily (n=21) | 160 mg dailyb (n=28) | |
|---|---|---|---|---|
| Best confirmed response, n (%)c | ||||
| Complete response | 0 | 1 (11) | 1 (5) | 0 |
| Partial response | 0 | 1 (11) | 3 (14) | 12 (43) |
| Stable diseased | 3 (25) | 6 (67) | 11 (52) | 12 (43) |
| Progressive disease | 7 (58) | 1 (11) | 3 (14) | 2 (7) |
| Not evaluated | 2 (17) | 0 | 3 (14) | 2 (7) |
| Confirmed ORR, n (%) [95% CI] | 0 [0–26] | 2 (22) [3–60] | 4 (19) [5–42] | 12 (43) [24–63] |
| Confirmed disease control rate, n (%) [95% CI] | 3 (25) [5–57] | 8 (89) [52–100] | 15 (71) [48–89] | 24 (86) [67–96] |
Data cutoff: January 27, 2020
Abbreviations: CI, confidence interval; EGFRex20ins, epidermal growth factor receptor gene exon 20 insertion; ORR, objective response rate; RECIST, Response Evaluation Criteria in Solid Tumors.
a
Includes 80 mg daily and 40 mg twice daily.
b
Patients treated with at least one dose of mobocertinib.
c
By RECIST version 1.1.
d
Stable disease observed ≥6 weeks after first study drug administration.